Literature DB >> 1824616

Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness.

R J Smith1, J E Chin, L M Sam, J M Justen.   

Abstract

Recombinant human interleukin-1 alpha (IL-1 alpha) and recombinant human IL-1 beta stimulate matrix proteoglycan degradation and inhibit glycosaminoglycan synthesis in bovine nasal cartilage explants. A 17-kd human recombinant IL-1 receptor antagonist protein (IRAP) caused a concentration-dependent (0.2-200 ng/ml) suppression of the effects of IL-1 alpha and IL-1 beta in cartilage organ cultures. IRAP inhibited the binding of radiolabeled IL-1 alpha to rabbit articular chondrocytes. Matrix metalloproteinase (collagenase, gelatinase, and stromelysin) and prostanoid production by IL-1-activated rabbit articular chondrocytes was also suppressed by IRAP. These results could have potential significance in the development of a new antiarthritis therapy based on an IRAP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824616     DOI: 10.1002/art.1780340112

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

1.  Fibronectin-fragment-induced cartilage chondrolysis is associated with release of catabolic cytokines.

Authors:  G A Homandberg; F Hui; C Wen; C Purple; K Bewsey; H Koepp; K Huch; A Harris
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

Review 2.  [New drugs for treatment of juvenile idiopathic arthritis].

Authors:  Gerd Horneff
Journal:  Z Rheumatol       Date:  2019-09       Impact factor: 1.372

3.  Physiologic deformational loading does not counteract the catabolic effects of interleukin-1 in long-term culture of chondrocyte-seeded agarose constructs.

Authors:  Eric G Lima; Andrea R Tan; Timon Tai; Liming Bian; Gerard A Ateshian; James L Cook; Clark T Hung
Journal:  J Biomech       Date:  2008-09-26       Impact factor: 2.712

4.  [Principles of surgical therapy concepts for postoperative and chronic osteomyelitis].

Authors:  F Kutscha-Lissberg; U Hebler; T Kälicke; S Arens
Journal:  Orthopade       Date:  2004-04       Impact factor: 1.087

Review 5.  Treatment of rheumatoid arthritis with IL-1 inhibitors.

Authors:  C Gabay; W P Arend
Journal:  Springer Semin Immunopathol       Date:  1998

6.  [Why do osteosyntheses fail? The problem with biomechanics and biology].

Authors:  F Kutscha-Lissberg; K F Hopf
Journal:  Unfallchirurg       Date:  2003-09       Impact factor: 1.000

Review 7.  Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Expert Opin Investig Drugs       Date:  2008-04       Impact factor: 6.206

8.  Human recombinant interleukin-1 receptor antagonist blocks bone resorption induced by interleukin-1 beta but not interleukin-1 alpha.

Authors:  R A Chole; S P Tinling; B T Faddis
Journal:  Calcif Tissue Int       Date:  1994-07       Impact factor: 4.333

9.  Interleukin-1 receptor antagonist production in cultured synovial cells from patients with rheumatoid arthritis and osteoarthritis.

Authors:  Y Fujikawa; M Shingu; T Torisu; S Masumi
Journal:  Ann Rheum Dis       Date:  1995-04       Impact factor: 19.103

10.  IL-1 has no direct role in the IGF-1 non-responsive state during experimentally induced arthritis in mouse knee joints.

Authors:  P J Verschure; L A Joosten; F A Van de Loo; W B Van den Berg
Journal:  Ann Rheum Dis       Date:  1995-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.